logo

TLPH

Talphera·NASDAQ
--
--(--)
--
--(--)

TLPH fundamentals

Talphera (TLPH) released its earnings on Nov 12, 2025: revenue was 1.00K (YoY --), beat estimates; EPS was -0.11 (YoY +15.38%), beat estimates.
Revenue / YoY
1.00K
--
EPS / YoY
-0.11
+15.38%
Report date
Nov 12, 2025
TLPH Earnings Call Summary for Q3,2025
  • NEPHRO Study: Delays push completion to H1 2026; 2/6 new sites activated with similar enrollment rates.
  • FDA Process: Conditional approval for compassionate use in specific patient populations.
  • Capital: $21.3M cash, with sufficient funding through 2026.
  • Regulatory: Breakthrough designation maintains efficient engagement.
  • Commercial Readiness: Anticipated PMA approval in H2 2026.

Earnings

EPS
Revenue

Revenue & Expenses

Key Indicators

Talphera (TLPH) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Talphera (TLPH)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown

Balance Sheet

Talphera (TLPH)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown

Cash Flow

Talphera (TLPH)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown

Revenue Breakdown

Where does Talphera (TLPH) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:

Dividend

Track Talphera (TLPH) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield